Business Context and Reporting Period
This Form 8-K is filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) for the reporting period ending June 1, 2022. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI. The filing addresses a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate governance event rather than a periodic financial statement.
Material Changes
- Accounting Firm Merger: The company's former auditor, Dixon Hughes Goodman LLP ("DHG"), merged with BKD, LLP on June 1, 2022.
- New Auditor Engagement: The combined practice now operates as FORVIS, LLP. The Audit Committee approved FORVIS as the independent registered public accounting firm effective June 1, 2022.
- No Prior Consultations: The company confirmed it did not consult with BKD on accounting principles or audit opinions during the last two fiscal years or subsequent interim periods.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies related to financial performance are disclosed in this document. The primary disclosure is the administrative transition of the audit firm.
Investor Verification Checklist
- Verify the effective date of the engagement with FORVIS, LLP (June 1, 2022).
- Confirm the absence of any disagreements or consultations with the predecessor firm (BKD) regarding accounting principles.
- Review the concurrent filing of Exhibit 16.1 (Letter from FORVIS, LLP) for the auditor's concurrence with the company's statements.
- Note the discrepancy between the metadata company name ("Dogwood Therapeutics") and the actual registrant ("Virios Therapeutics").